Liquid Biopsy
The investigations that are conducted aim at the study of circulating tumor DNA (ctDNA, circulating tumor DNA) to search for genetic mutations capable of conferring sensitivity or resistance to so-called "molecular target" drug therapies. Currently, the use of liquid biopsy for the purpose of predictive diagnosis for pharmacological treatment is indicated in patients with non-small cell lung cancer (NSCLC) where there are difficulties in performing tissue biopsy which, while representing the traditional tool for monitoring the genetic evolution of the tumor, in some cases can be difficult to apply due to its invasiveness, or to the suboptimal clinical conditions of the patient or to the site of the tumor.